Patent ID: 9051278
Filing Date: 2015-06-09
Classification: A61K,A61P,C04B,C07D

Abstract:
1. A method for treatment of a disease state or condition selected from a carcinoma selected from a carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, or skin; a hematopoietic tumour of lymphoid lineage; a hematopoietic tumour of myeloid lineage; thyroid follicular cancer; a tumour of mesenchymal origin; a tumour of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoctanthoma; thyroid follicular cancer; Kaposi's sarcoma; glioblastoma multiforme; gliosarcoma; mantle cell lymphoma; endometrial cancer; multiple myeloma; and an advanced or metastatic solid tumor, which method comprises administering to a mammal in need thereof a compound of the formula (II): or a salt, or tautomer, N-oxide, or solvate thereof; wherein Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R R R R R X and provided that where the substituent group R 10 comprises or includes a carbocyclic or heterocyclic group, the said carbocyclic or heterocyclic group may be unsubstituted or may itself be substituted with one or more further substituent groups R 10 and wherein (a) such further substituent groups R 10 include carbocyclic or heterocyclic groups, which are not themselves further substituted; or (b) the said further substituents do not include carbocyclic or heterocyclic groups but are otherwise selected from the groups listed above in the definition of R 10 .